When Can We Expect A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?
When Can We Expect A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The US$1.3b market-cap company's loss lessened since it announced a US$108m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$77m, as it approaches breakeven. As path to profitability is the topic on Aurinia Pharmaceuticals' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company.
Aurinia Pharmicals Inc.(纳斯达克股票代码:AUPH)的业务可能即将取得重大成就,因此我们想对该公司进行一些阐述。Aurinia Pharmicals Inc. 是一家商业阶段的生物制药公司,专注于开发和商业化治疗美国医疗需求未得到满足的各种疾病的疗法。这家市值为13亿美元的公司自宣布整个财政年度亏损1.08亿美元以来,亏损有所减少,而最近十二个月的亏损为7700万美元,接近盈亏平衡。由于盈利之路是Aurinia Pharmicals投资者心目中的话题,因此我们决定评估市场情绪。下面我们将简要概述行业分析师对公司的期望。
View our latest analysis for Aurinia Pharmaceuticals
查看我们对Aurinia Pharmicals的最新分析
Aurinia Pharmaceuticals is bordering on breakeven, according to the 9 American Biotechs analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$12m in 2025. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 71% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
9位美国生物技术分析师表示,Aurinia Pharmicals已接近盈亏平衡。他们预计,该公司将在2024年蒙受最终亏损,然后在2025年产生1200万美元的正利润。因此,预计该公司将在大约两年后实现盈亏平衡。为了到2025年达到盈亏平衡点,公司每年必须以多快的速度增长?从分析师的估计来看,事实证明,他们预计该公司平均同比增长71%,这表明分析师充满信心。如果业务增长速度放缓,则盈利的时间将晚于预期。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231218/0-46ddb77c1883329346c444963c834de6-0-81069821adede02f3465a8a8067d4559.png/big)
We're not going to go through company-specific developments for Aurinia Pharmaceuticals given that this is a high-level summary, however, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
鉴于这是一份高级摘要,我们不打算详细介绍Aurinia Pharmicals的公司具体发展情况,但是请记住,通常生物技术公司的现金流周期不规律,具体取决于产品开发阶段。因此,高增长率并不是不寻常的,尤其是在公司处于投资期时。
Before we wrap up, there's one aspect worth mentioning. Aurinia Pharmaceuticals currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
在我们总结之前,有一个方面值得一提。Aurinia Pharmicals目前的资产负债表上没有债务,这对于一家亏损的生物技术公司来说是罕见的,该公司的债务相对于其股本来说通常很高。该公司目前完全依靠股东资金运营,没有债务义务,这减少了对还款的担忧,使其成为一项风险较小的投资。
Next Steps:
后续步骤:
This article is not intended to be a comprehensive analysis on Aurinia Pharmaceuticals, so if you are interested in understanding the company at a deeper level, take a look at Aurinia Pharmaceuticals' company page on Simply Wall St. We've also put together a list of relevant aspects you should look at:
本文不打算对Aurinia Pharmicals进行全面分析,因此,如果你有兴趣更深入地了解该公司,请查看Aurinia Pharmaceuticals在Simply Wall St上的公司页面。我们还整理了一份你应该考虑的相关方面清单:
- Valuation: What is Aurinia Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Aurinia Pharmaceuticals is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Aurinia Pharmaceuticals's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Aurinia Pharmicals今天的价值是多少?未来的增长潜力是否已经被考虑在价格中?我们的免费研究报告中的内在价值信息图有助于直观地了解Aurinia Pharmicals目前是否被市场错误定价。
- 管理团队:经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Aurinia Pharmicals董事会成员以及首席执行官的背景。
- 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在这里浏览我们免费列出的这些优质股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。